|
|
| TX-RAD | TX-RAD is a new investigational product which is in the preclinical development stage to treat Rheumatoid Arthritis, planned to represent an expanded population of autologous antigen-specific Tr1 lymphocytes.
TX-RAD treatment will be an infusion bag containing autologous anti-joint Tr1 cells which will be produced thanks to TxCell's manufacturing process. The expanded population of autologous Tr1 cell clones will be injected intravenously in the patient.
TX-RAD will have to be administered to patients in a period of active inflammation. As an autologous cellular therapy, TX-RAD Tr1 cell treatment will reflect a more physiologic mechanism of action against inflammation compared to pharmaceutical compounds (anti-TNF and other targets) due to a more physiologic migration, activation and effector functions.
Product
|
TX-RAD Autologous anti-joint regulatory type 1 T lymphocytes
|
Concept |
TX-RAD is an investigational product in a new class of autologous cellular immunotherapy that is uniquely designed to regulate the patient's own immune system.
TX-RAD holds promise because it may provide patients with meaningful clinical benefits with low toxicity. |
Indications |
Chronic Inflammatory Joint Diseases:
- Rheumatoid arthritis
- Juvenile arthritis
- Psoriatic arthritis
- Ankylosing Spondylitis
| | Clinical Phase |
Preclinical for patients with chronic active Rheumatoid Arthritis:
Toxicity and Efficacy studies
|
Market
| TxCell's main aim is to enable the feasibility of its Rheumatoid Arthritis treatment to all moderate to severe patients. Rheumatoid arthritis affects approximately 6 million people in major countries. |
Collaborations |
Co-development, research and out-licensing
agreements are available
Contact:
Cet e-mail est protg contre les robots collecteurs de mails, votre navigateur doit accepter le Javascript pour le voir
|
|
|
|
